Treatment of ALK rearranged positive lung cancer requires sequential use of first‐, second‐, and third‐generation ALK inhibitors, but the sensitivity of these drugs differs for each resistance, and individualized treatment will be required for patients. The gene discussed is ALK; the disease is lung carcinoma.